skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Drug Interactions

Drug Interactions between CCR5 Antagonist and Other Drugs

(Last updated:3/27/2012; last reviewed:2/12/2013)

Click here to view this table as an image

(This table provides information relating to pharmacokinetic (PK) interactions between maraviroc (MVC) and non antiretroviral (ARV) drugs. For interactions between ARV agents and for dosing recommendations, please refer to Table 16b.

 

Table 15e. Drug Interactions between CCR5 Antagonist and Other Drugs
Concomitant Drug
Class/Name 
CCR5 Antagonist  Effect on CCR5 Antagonist or Concomitant Drug Concentrations Dosing Recommendations and Clinical Comments 
Anticonvulsants
Carbamazepine
Phenobarbital
Phenytoin
MVC  ↓ MVC possible If used without a strong CYP3A inhibitor, use MVC 600 mg BID or an alternative antiepileptic agent.
Antifungals
Itraconazole MVC  ↑ MVC possible Dose: MVC 150 mg BID
Ketoconazole MVC MVC AUC ↑ 400% Dose: MVC 150 mg BID
Voriconazole MVC  ↑ MVC possible Consider dose reduction to MVC 150 mg BID
Antimycobacterials
Clarithromycin MVC  ↑ MVC possible Dose: MVC 150 mg BID
Rifabutin MVC  ↓ MVC possible If used without a strong CYP3A inducer or inhibitor, use MVC 300 mg BID.
If used with a strong CYP3A inhibitor, use MVC 150 mg BID.
Rifampin MVC  MVC AUC ↓ 64% Co-administration is not recommended.
If co-administration is necessary, use MVC 600 mg BID.
If co-administered with a strong CYP3A inhibitor, use MVC 300 mg BID.
Rifapentine MVC  ↓ MVC expected Do not co-administer.
Herbal Products
St. John’s wort MVC MVC possible Co-administration is not recommended.
Hormonal Contraceptives
Hormonal contraceptives MVC No significant effect on ethinyl estradiol or levonorgestrel Safe to use in combination
Key to Abbreviations: ARV = antiretroviral, AUC = area under the curve, BID = twice daily, CYP = cytochrome P, MVC = maraviroc, PK = pharmacokinetic